1.51 BONUS! Study Time Reduction Using Surrogate End Points with Dr. Emerson Chen
Apr 02, 2019•26 min
Episode description
In this BONUS episode, we sit down for a quick interview with Dr. Emerson Chen of OHSU on his recent paper in JAMA Internal Medicine on how using surrogate end points as opposed to overall survival for FDA approval for oncology drugs only results in a reduced drug development time of approximately 11 months.
Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351
Back us on Patreon! www.patreon.com/plenarysession
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast